Endogenous angiotensin II enhances atherogenesis in apoprotein E-deficient mice with renovascular hypertension through activation of vascular smooth muscle cells

Life Sciences

Volumn 80, Issue 11, 2007, Pages 1057-1063

  Heo, Hye Jin ^a   Yun, Mi Ran ^a   Jung, Keun Hwa ^a   Lee, Ji Young ^a   Park, Ji Young ^a   Lee, Seung Jin ^a   Bae, Sun Sik ^a   Lee, Won Suk ^a   Kim, Chi Dae ^a  

^a MRC for Ischemic Tissue Regeneration   (South Korea)

Author keywords

Angiotensin II; Atherosclerosis; Foam cell; Hypertension

Indexed keywords

ANGIOTENSIN II; APOLIPOPROTEIN E; LOW DENSITY LIPOPROTEIN; SCAVENGER RECEPTOR A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA SINUS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL STIMULATION; CONTROLLED STUDY; HORMONE SYNTHESIS; HYPERLIPOPROTEINEMIA TYPE 3; IMMUNOHISTOCHEMISTRY; MACROPHAGE; NONHUMAN; QUANTITATIVE ANALYSIS; RENOVASCULAR HYPERTENSION; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CELL LINE; CULTURE MEDIA, CONDITIONED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; FOAM CELLS; GENE SILENCING; HYPERTENSION, RENOVASCULAR; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOENZYME TECHNIQUES; MICE; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; SINUS OF VALSALVA;

MUS;

EID: 33846798397     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.11.046     Document Type: Article

References (30)

1. Alderman M.H., Ooi W.L., Cohen H., Madhavan S., Sealey J.E., and Laragh J.H. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. American Journal of Hypertension 10 1 (1997) 1-8
2. Alexander R.W. Theodore Cooper Memorial Lecture. Hypertension and the atherogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension 25 2 (1995) 155-161
3. Capers Q., Alexander R.W., Lou P., De Leon H., Wilcox J.N., Ishizaka N., Howard A.B., and Taylor W.R. Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats. Hypertension 30 6 (1997) 1397-1402
4. Chobanian A.V., and Alexander R.W. Exacerbation of atherosclerosis by hypertension. Potential mechanisms and clinical implications. Archives Internal Medicine 23 17 (1996) 1952-1956
5. Daugherty A., Manning M.W., and Cassis L.A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. Journal of Clinical Investigation 105 11 (2000) 1605-1612
6. Fox J., Guan S., Hymel A.A., and Navar L.G. Dietary Na and ACE inhibition effects on renal tissue angiotensin I and II and ACE activity. American Journal of Physiology 262 (1992) F902-F909
7. Keidar S., Attias J., Smith J., Breslow J.L., and Hayek T. The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochemical and Biophysical Research Communications 30 3 (1997) 622-625
8. Keidar S., Attias J., Heinrich R., Coleman R., and Aviram M. Angiotensin II atherogenicity in apolipoprotein E deficient mice is associated with increased cellular cholesterol biosynthesis. Atherosclerosis 146 2 (1999) 249-257
9. Keidar S., Heinrich R., Kaplan M., Hayek T., and Aviram M. Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized LDL: a possible role for interleukin-6. Arteriosclerosis, Thrombosis and Vascular Biology 21 9 (2001) 1464-1469
10. Knowles J.W., and Maeda N. Genetic modifiers of atherosclerosis in mice. Arteriosclerosis, Thrombosis and Vascular Biology 20 11 (2000) 2336-2345
11. Kowala M.C., Grove R.I., and Aberg G. Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters. Fosinopril reduces plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids. Atherosclerosis 108 1 (1994) 61-72
12. Laursen J.B., Rajagopalan S., Galis Z., Tarpey M., Freeman B.A., and Harrison D.G. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 4 3 (1997) 588-593
13. Lithell H. Pathogenesis and prevalence of atherosclerosis in hypertensive patients. American Journal of Hypertension 7 7 Pt 2 (1994) 2S-6S
14. Liu Y., Liu T., McCarron R.M., Spatz M., Feuerstein G., Hallenbeck J.M., and Siren A.L. Evidence for activation of endothelium and monocytes in hypertensive rats. American Journal of Physiology 270 (1996) H2125-H2131
15. Mazzolai L., and Hayoz D. The renin-angiotensin system and atherosclerosis. Current Hypertension Report 8 1 (2006) 47-53
16. Mazzolai L., Pedrazzini T., Nicoud F., Gabbiani G., Brunner H.R., and Nussberger J. Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension 35 4 (2000) 985-991
17. -/- mice. Hypertension 44 3 (2004) 277-282
18. Nakashima Y., Plump A.S., Raines E.W., Breslow J.L., and Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arteriosclerosis and Thrombosis 14 1 (1994) 133-140
19. O'Leary D.H., Polak J.F., Kronmal R.A., Manolio T.A., Burke G.L., and Wolfson S.K. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. The New England Journal of Medicine 7 1 (1999) 14-22
20. Saini H.K., Xu Y.J., Arneja A.S., Tappia P.S., and Dhalla N.S. Pharmacological basis of different targets for the treatment of atherosclerosis. Journal of Cellular and Molecular Medicine 9 4 (2005) 818-839
21. Sakamoto H., Aikawa M., Hill C.C., Weiss D., Taylor W.R., Libby P., and Lee R.T. Biomechanical strain induces class A scavenger receptor expression in human monocyte/macrophages and THP-1 cells: a potential mechanism of increased atherosclerosis in hypertension. Circulation 104 (2001) 109-114
22. Schieffer B., Schieffer E., Hilfiker-Kleiner D., Hilfiker A., Kovanen P.T., Kaartinen M., Nussberger J., Harringer W., and Drexler H. Expression of angiotensin II and interleukin-6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 101 (2000) 1372-1378
23. Stephan Z.F., and Yirachek E.C. Rapid fluorometric assay of LDL receptor activity by Dil-labeled LDL. Journal of Lipid Research 43 (1993) 325-330
24. Tedgui A., and Mallat Z. Hypertension: a novel regulator of adaptive immunity in atherosclerosis?. Hypertension 44 (2004) 257-258
25. Teupser D., Thiery J., and Seidel D. Alpha-tocopherol down-regulates scavenger receptor activity in macrophages. Atherosclerosis 144 1 (1999) 109-115
26. Tham D.M., Martin-McNulty B., Wang Y.X., Da Cunha V., Wilson D.W., Athanassious C.N., Powers A.F., Sullivan M.E., and Rutledge J.C. Angiotensin II injures the arterial wall causing increased aortic stiffening in apolipoprotein E-deficient mice. American Journal of Physiology 283 6 (2002) R1442-R1449
27. Weiss D., Kools J.J., and Taylor W.R. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 103 (2001) 448-454
28. Wiesel P., Mazzolai L., Nussberger J., and Pedrazzini T. Two-kidney, one clip and one-kidney, one clip hypertension in mice. Hypertension 29 4 (1997) 1025-1030
29. Xie Q.-Y., Sun M., Yang T.-I., and Sun Z.-L. Losartan reduces monocyte chemoattractant protein-1 expression in aortic tissues of 2K1C hypertensive rats. International Journal of Cardiology 110 (2006) 60-66
30. Xu C.P., Glagov S., Zatina M.A., and Zarins C.K. Hypertension sustains plaque progression despite reduction of hypercholesterolemia. Hypertension 18 2 (1991) 123-129